TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01241240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)
Description: One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
Description: One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
Study: NCT01212692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mentally stimulating activities
Description: The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mentally stimulating activities
Description: The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
Study: NCT01486329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXM01
Description: Live anti-angiogenic cancer vaccine drink solution, escalating dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drink solution
Study: NCT04319991

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics product
Description: This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
Study: NCT01110512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavonid
Description: Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daflon
Description: Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day
Study: NCT01660373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: 0.4ug/kg/min for 30min followed by 0.1ug/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: loading dose(180mg) followed by maintenance dose(90mg bid)
Study: NCT03605550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC596
Description: Oral tablets

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Cycle1
Study: NCT03523585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
Study: NCT04319991

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics product
Description: This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
Study: NCT03523585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Investigator's choice Standard of Care when combined with trastuzumab or lapatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Investigator's choice Standard of Care when combined with capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Investigator's choice Standard of Care when combined with capecitabine
Study: NCT03940521

Intervention type: OTHER
Intervention: Bioclinical evaluation
Description: 50-100ml blood extracted for flow cytometry and qPCR
Study: NCT04185870

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D scan
Description: All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum.
Study: NCT00266032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)
Description: 3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)
Description: 3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)
Description: 13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
Study: NCT02977871

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder flap
Description: Performing uterine incision and cesarean section with a bladder flap.
Study: NCT01379937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK1562902A Formulation 1
Description: Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK1562902A Formulation 1
Description: Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK1562902A Formulation 2
Description: Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine GSK1562902A Formulation 2
Description: Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™
Description: Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™
Description: Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™
Description: Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™
Description: Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™ Junior
Description: Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
Study: NCT04185870

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard photography
Description: All participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
Study: NCT02602899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PINS'Deep Brain Stimulator device
Description: deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
Study: NCT01550471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo
Description: Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase
Description: Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo
Description: QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris
Description: QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase
Description: Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
Description: Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
Study: NCT00455767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-hNE4
Description: I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01134315

Intervention type: DRUG
Intervention: Paricalcitol

Intervention type: DRUG
Intervention: Calcitriol
Study: NCT04157621

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active taVNS
Description: Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.
Study: NCT03141073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: BID oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID oral administration
Study: NCT01737450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study: NCT02097043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-7218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-7218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-7218

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02891811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
Study: NCT00833625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT (FDG PET/CT)
Description: PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Testings
Description: Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
Study: NCT00828828

Intervention type: BIOLOGICAL
Intervention: Influenza Vaccine
Description: One 0.5 ml dose of influenza vaccine injected intramuscular.

Intervention type: BIOLOGICAL
Intervention: Influenza Vaccine
Description: One 0.5 ml dose of influenza vaccine injected intramuscular.
Study: NCT01379937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™ Junior
Description: Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
Study: NCT02891811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100mg orally on days 1-28 in patients \<75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 25mg p.o. on days 1-21 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients \<75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients \<75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
Study: NCT00812747

Intervention type: OTHER
Intervention: observation
Study: NCT00736879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, Once Daily, Up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, Once Daily, Up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, Once Daily, Up to 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, Once Daily, Up to 24 weeks
Study: NCT02010827

Intervention type: BIOLOGICAL
Intervention: isoglycemic intravenous glucose infusion and Glucagon infusion, day C
Description: Infusion of 0.8ng/kg/min glucagon from time 0-25min

Intervention type: BIOLOGICAL
Intervention: isoglycemic intravenous glucose infusion and Glucagon infusion, day C
Description: Infusion of 0.8ng/kg/min glucagon from time 0-25min

Intervention type: BIOLOGICAL
Intervention: Oral glucose tolerance test, day A
Study: NCT01379937

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™ Junior
Description: Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
Study: NCT02010827

Intervention type: BIOLOGICAL
Intervention: Oral glucose tolerance test, day A

Intervention type: BIOLOGICAL
Intervention: intravenous iv glucose infusion, day B

Intervention type: BIOLOGICAL
Intervention: intravenous iv glucose infusion, day B
Study: NCT01121731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon α-5
Description: 3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-α5 plus Interferon-α 2b
Description: Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon α-2b (INTRON® A)
Description: 3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
Study: NCT00931736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.
Study: NCT01698112

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed High Dose
Description: 26 gram flaxseed intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed Low Dose
Description: 13 grams flaxseed
Study: NCT01669096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational TB vaccine GSK 692342
Description: 2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
Study: NCT03923738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.
Study: NCT01822704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity whole body vibration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity whole body vibration

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Leg exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg exercises
Study: NCT00454701

Intervention type: DRUG
Intervention: Alefacept exposure
Description: Observational
Study: NCT03583164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorofim
Description: 30mg oral tablets
Study: NCT03246620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine oro-dispersible 5Mg Tab
Description: Patient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol 2Mg encapsulated Tab
Description: Patient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam 2Mg encapsulated Tab
Description: Patient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet
Study: NCT03433274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendyne Mitral Valve System
Description: Mitral valve replacement
Study: NCT02004392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Study: NCT02860377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recorded maternal voice
Description: A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. ~At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up.
Study: NCT03912571

Intervention type: DIAGNOSTIC_TEST
Intervention: Structural 3T MRI
Description: measures of global and hippocampal atrophy)

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Based Perfusion Imaging
Description: brain blood flow

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Based Perfusion Imaging
Description: brain blood flow

Intervention type: DIAGNOSTIC_TEST
Intervention: VR-CO2 MRI Scans
Description: reduced vaso reactivity to carbon dioxide

Intervention type: DIAGNOSTIC_TEST
Intervention: VR-CO2 MRI Scans
Description: reduced vaso reactivity to carbon dioxide
Study: NCT02860377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recorded stranger's voice
Description: A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.
Study: NCT02494362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer gaming hand exercise regimen.
Description: Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.